The Efficacy and Safety of Liraglutide on Body Weight Loss in Obese and Overweight Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

414

Participants

Timeline

Start Date

August 18, 2020

Primary Completion Date

December 31, 2022

Study Completion Date

April 15, 2023

Conditions
ObeseOverweight
Interventions
DRUG

Liraglutide

Liraglutide Injection, once a day, injected subcutaneously on the sites of abdomen, thigh or upper arm. The initial dose of Liraglutide Injection will be 0.6 mg per day. The dose is escalated every one to two weeks to reduce the gastrointestinal symptoms. At Week 7, the dose is increased to 3.0 mg per day. For the subjects who are not able to tolerate the target dose of 3.0 mg,the dose is reduced to 2.4 mg a day and escalated to the dose to 3.0 mg within two weeks. If the subjects are still unable to tolerate this dose (3.0 mg), the treatment is terminated.

DRUG

Placebo

Placebo Injection, once a day, injected subcutaneously on the sites of abdomen, thigh or upper arm. The initial dose of Placebo Injection will be 0.6 mg per day. The dose is escalated every one to two weeks to reduce the gastrointestinal symptoms. At Week 7, the dose is increased to 3.0 mg per day. For the subjects who are not able to tolerate the target dose of 3.0 mg,the dose is reduced to 2.4 mg a day and escalated to the dose to 3.0 mg within two weeks. If the subjects are still unable to tolerate this dose (3.0 mg), the treatment is terminated.

Trial Locations (1)

200032

Zhongshan Hosital, Fudan University, Shanghai

All Listed Sponsors
lead

Shanghai Zhongshan Hospital

OTHER

NCT04605861 - The Efficacy and Safety of Liraglutide on Body Weight Loss in Obese and Overweight Patients | Biotech Hunter | Biotech Hunter